SCHEMBL5573185

SCHEMBL5573185

CC(C)(C)c1ccc(C=CC=CC(=O)O)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.62
TRPV1 Q8NER1 2/20 0.53
SMN1; SMN2 Q16637 4/20 0.49
NPC1 O15118 3/20 0.49
RAB9A P51151 3/20 0.49
MAPT P10636 3/20 0.49
ALDH1A1 P00352 2/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
RXRA P19793 1/20 0.48
NR1H4 Q96RI1 1/20 0.48
LMNA P02545 3/20 0.47
HPGD P15428 3/20 0.47
MAPK1 P28482 3/20 0.47
KDM4E B2RXH2 2/20 0.47
POLB P06746 1/20 0.47
HSD17B10 Q99714 2/20 0.46
GAA P10253 1/20 0.46
TP53 P04637 1/20 0.45
CYP3A4 P08684 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5573179 1.00 CYP1A2 (0.62) CYP1A2TRPV1SMN1; SMN2NPC1RAB9A
SCHEMBL4001354 0.87 CYP1A2 (0.75) CYP1A2TRPV1SMN1; SMN2NPC1RAB9A
SCHEMBL818742 0.87 CYP1A2 (0.75) CYP1A2TRPV1SMN1; SMN2NPC1RAB9A
SCHEMBL846833 0.87 CYP1A2 (0.75) CYP1A2TRPV1SMN1; SMN2NPC1RAB9A
SCHEMBL2643473 0.84 CA1 (0.54) CYP1A2TRPV1MAPTNR1H4LMNA
SCHEMBL2643476 0.84 CA1 (0.54) CYP1A2TRPV1MAPTNR1H4LMNA
SCHEMBL29349761 0.82 CYP1A2 (0.59) CYP1A2TRPV1SMN1; SMN2NPC1RAB9A
SCHEMBL5572624 0.82 CYP1A2 (0.62) CYP1A2HDAC1HDAC3HDAC2HDAC10
SCHEMBL5572620 0.82 CYP1A2 (0.62) CYP1A2HDAC1HDAC3HDAC2HDAC10
SCHEMBL4805633 0.82 CYP1A2 (0.68) CYP1A2TRPV1SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101489989-A Pentadiene amide derivative KYOWA HAKKO KIRIN CO LTD (JP) 2009-07-22 CN disclosed
EP-1057815-B1 CYCLIC AMIDE COMPOUNDS KOWA CO (JP) 2007-09-05 EP disclosed
US-6645957-B2 Useful in preventing and treating allergic immunological diseases; treating asthma, atopic dermatitis, allergic rhinitis, inflammatory large bowel disease, contact dermatitis KOWA CO., LTD. (JP) 2003-11-11 US disclosed
US-20030096828-A1 Cyclic amide compound KOWA CO., LTD. (JP) 2003-05-22 US disclosed
US-6448242-B1 COMPOUND HAVING A STRONG INHIBITORY EFFECT ON THE PRODUCTION OF AN IGE ANTIBODY; ANTIALLERGENS KOWA CO., LTD. (JP) 2002-09-10 US disclosed
EP-1057815-A1 CYCLIC AMIDE COMPOUNDS Kowa Co., Ltd. (JP) 2000-12-06 EP disclosed
EP-0162975-A1 P-alkyl or cycloalkyl phenoxy alkanols and alkanol esters and use for the treatment of allergic conditions PHARMACO DEVELOPMENT PARTNERS (US) 1985-12-04 EP disclosed
US-4543362-A P-Alkyl or cycloalkyl phenoxy alkanols and alkanol esters and process for the treatment of allergic conditions Berger, Frank M. (US) 1985-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096828-A1 Cyclic amide compound CMA1, HRH2, HRH4 CYP1A2 516/4885TRPV1 305/4885SMN1; SMN2 4567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.